This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022Hynes Convention Center, Boston

Adrian Briggs, Ph.D.
VP, Head of Platform Technologies at Shape Therapeutics


Adrian Briggs, PhD, is the Head of Platform Technologies at Shape Therapeutics (ShapeTX), where he oversees early research and development of ShapeTX’s gene therapy payload and engineered delivery vehicle platforms. Prior to ShapeTX, Dr. Briggs led research teams in CAR-T cell therapy at Juno Therapeutics, Celgene and Bristol-Myers Squibb, focusing on the technology underpinning applications from binder discovery to accelerated manufacturing. Prior to Juno, he led R&D at AbVitro, a George Church-lab startup whose antibody and T-cell receptor discovery platform was acquired by Juno in 2016 for >$125M. Before AbVitro, Dr. Briggs performed postdoctoral work in gene editing in the Church lab at Harvard Medical School, and earned his PhD in ancient DNA sequencing as a core member of the Neandertal Genome Project team in Leipzig, Germany.